Financial Performance - The company's revenue for Q1 2025 was ¥350,884,969.11, a decrease of 19.60% compared to ¥436,441,198.76 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥8,080,860.79, representing a decline of 854.01% from a profit of ¥1,071,720.66 in the previous year[5] - The company's operating profit turned negative at ¥-6,673,526.50, down from a profit of ¥2,720,970.17 in the previous period[17] - Net profit for the period was a loss of ¥8,426,252.98 compared to a loss of ¥264,826.54 in the previous period, indicating a significant decline in profitability[18] - Basic and diluted earnings per share were both ¥-0.0203, compared to ¥0.0027 in the previous period, reflecting a substantial decrease[18] Cash Flow - The net cash flow from operating activities improved to ¥1,658,133.01, a significant increase of 104.28% compared to a negative cash flow of ¥38,737,542.37 in Q1 2024[5] - Net cash flow from operating activities was 1,658,133.01, a significant improvement from a negative cash flow of -38,737,542.37 in the previous period[21] - Cash received from sales of goods and services was ¥401,580,869.23, down from ¥420,445,869.80, a decrease of approximately 4.1% year-over-year[20] - Cash inflow from investment activities totaled 256,036,805.39, compared to 50,195,671.23 in the prior period, indicating a strong increase in investment recovery[21] - Cash outflow from investment activities was 321,572,288.15, up from 67,653,847.10, leading to a net cash flow from investment activities of -65,535,482.76, worsening from -17,458,175.87[21] - Total cash flow from financing activities resulted in a net outflow of -19,708,529.29, compared to -14,143,681.47 in the previous period[22] Assets and Liabilities - The total assets at the end of Q1 2025 were ¥2,616,249,615.91, a slight decrease of 0.27% from ¥2,623,334,426.70 at the end of the previous year[5] - Total current assets amount to CNY 2,007,317,551.25, slightly up from CNY 1,998,640,598.09 at the beginning of the period[15] - Total liabilities increased slightly to ¥804,339,369.72 from ¥802,997,927.54, indicating a stable financial position[16] - Non-current liabilities decreased to ¥174,021,754.03 from ¥187,408,532.33, a reduction of about 7.1% year-over-year[16] - The total equity attributable to shareholders decreased to ¥1,650,047,561.50 from ¥1,658,128,422.29, a decline of approximately 0.5%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 24,149[12] - The largest shareholder, Shanghai Lanwei Investment Co., holds 37.34% of shares, totaling 149,554,017 shares[12] Operational Efficiency - The company reported a significant increase in prepayments by 119.12%, rising to ¥10,423,796.74 from ¥4,757,068.96[10] - Financial expenses surged by 226.25% to ¥747,936.18, primarily due to a reduction in supplier discount income[10] - The company recorded a decrease in income tax expenses by 48.18%, amounting to ¥1,338,717.60, due to reduced profits[10] - Cash paid for employee compensation was 70,124,452.22, slightly up from 69,042,247.42, showing stable labor costs[21] - The company’s cash flow from operating activities was impacted by a total outflow of 404,955,588.09, down from 464,780,873.64, indicating improved operational efficiency despite higher outflows[21]
兰卫医学(301060) - 2025 Q1 - 季度财报